Allendale, NJ, October 10, 2007 – Lonza is extending its new branding concept to its prebiotic fiber ingredient, FiberAid®. Earlier this year, Lonza introduced a new quality seal and branding concept for its lead health ingredient, Carnipure™. The new FiberAid® quality seal is graphically in line with the Carnipure™ quality seal which has been tested with end consumers and has been rated as trustworthy, high quality and modern.
Both the FiberAid® and the Carnipure™ quality seals can be used on end consumer products. Products carrying these quality seals on the packaging show the consumer that they contain premium ingredients from Lonza, a high quality supplier based in Switzerland.
“We are glad to now have a consistent look for our health ingredients, as recognizability is key. The new branding concept also reflects the quality and reliability that make Lonza’s nutrition products trusted by both our customers and the end consumers,” says Reto Renggli, Director of Marketing & Sales for Nutrition at Lonza.
Along with the new branding, Lonza has launched the new product website www.fiberaid.com, where the main benefits and characteristics of FiberAid® are described.
FiberAid® is a premium soluble prebiotic fiber that offers superior benefits for gastrointestinal health combined with excellent digestive tolerance and technological properties. It is highly soluble in hot or cold water, stable against a wide pH and temperature range and forms low viscosity solutions. Composed of larch arabinogalactan, FiberAid® has been approved by the US FDA and other authorities. It is extracted by Lonza via a patented process (US 5756098, EP 866808 and other patents) from larch trees that grow in abundance in the United States. It is self-affirmed GRAS (Generally Recognized As Safe) with FDA notification.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information please contact:
NAFTA Head of Sales & Marketing - Nutrition
Tel +1 201 316 9333
Fax +1 201 785 1364